The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Frontline ibrutinib-FCR for younger CLL patients: Phase II results
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the single-arm, multi-center, Phase II trial (NCT02251548) of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as an initial treatment for younger patients with chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
